Replies to post #119027 on Biotech Values

[efar]

In today's 8-K AVEO pushed back the expected date for TIVO-1 phase III topline data from mid-2011 to Q4. Since this is an event based trial, the extended timeline could bode well for the outcome. Here's the exact language:

“We look forward to reviewing top-line data from TIVO-1, our pivotal Phase 3 trial for tivozanib, later this year. As an oncology trial with the primary endpoint of progression-free survival, the timeline for TIVO-1 is entirely dependent upon the accumulation of qualifying events. Based upon the current event-rate, we do not anticipate top-line TIVO-1 data until at least the fourth quarter of this year.”